Medically Actionable Pathogenic Variants in a Population of 13,131 Healthy Elderly Individuals - PubMed

Medically Actionable Pathogenic Variants in a Population of 13,131 Healthy Elderly Individuals - PubMed

Medically Actionable Pathogenic Variants in a Population of 13,131 Healthy Elderly Individuals

Paul Lacaze 1, Robert Sebra 2 3, Moeen Riaz 4, Jane Tiller 4, Jerico Revote 4, James Phung 4, Emily J Parker 4, Suzanne G Orchard 4, Jessica E Lockery 4, Rory Wolfe 4, Maya Strahl 2, Ying C Wang 2, Rong Chen 2 3, Daniel Sisco 3, Todd Arnold 3, Bryony A Thompson 5, Daniel D Buchanan 5 6, Finlay A Macrae 5, Paul A James 5, Walter P Abhayaratna 7, Trevor J Lockett 8, Peter Gibbs 9, Andrew M Tonkin 4, Mark R Nelson 4 10, Christopher M Reid 4 11, Robyn L Woods 4, Anne M Murray 12, Ingrid Winship 5, John J McNeil 4, Eric Schadt 2 3

Affiliations 

• PMID: 32606442
 
• DOI: 10.1038/s41436-020-0881-7

Abstract

Purpose: To measure the prevalence of medically actionable pathogenic variants (PVs) among a population of healthy elderly individuals.

Methods: We used targeted sequencing to detect pathogenic or likely pathogenic variants in 55 genes associated with autosomal dominant medically actionable conditions, among a population of 13,131 individuals aged 70 or older (mean age 75 years) enrolled in the ASPirin in Reducing Events in the Elderly (ASPREE) trial. Participants had no previous diagnosis or current symptoms of cardiovascular disease, physical disability or dementia, and no current diagnosis of life-threatening cancer. Variant curation followed American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) standards.

Results: One in 75 (1.3%) healthy elderly individuals carried a PV. This was lower than rates reported from population-based studies, which have ranged from 1.8% to 3.4%. We detected 20 PV carriers for Lynch syndrome (MSH6/MLH1/MSH2/PMS2) and 13 for familial hypercholesterolemia (LDLR/APOB/PCSK9). Among 7056 female participants, we detected 15 BRCA1/BRCA2 PV carriers (1 in 470 females). We detected 86 carriers of PVs in lower-penetrance genes associated with inherited cardiac disorders.

Conclusion: Medically actionable PVs are carried in a healthy elderly population. Our findings raise questions about the actionability of lower-penetrance genes, especially when PVs are detected in the absence of symptoms and/or family history of disease.

Keywords: genetic testing; healthy elderly; medical actionability; pathogenic variants; penetrance.

Similar articles

• Familial Hypercholesterolemia.

  Youngblom E, Pariani M, Knowles JW.2014 Jan 2 [updated 2016 Dec 8]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2020.PMID: 24404629 Free Books & Documents. Review.
• Penetrance and the Healthy Elderly.

  Lacaze P, Winship I, McNeil J.Genet Test Mol Biomarkers. 2017 Nov;21(11):637-640. doi: 10.1089/gtmb.2017.0126. Epub 2017 Sep 6.PMID: 28876137 Free PMC article.
• Association of Rare Pathogenic DNA Variants for Familial Hypercholesterolemia, Hereditary Breast and Ovarian Cancer Syndrome, and Lynch Syndrome With Disease Risk in Adults According to Family History.

  Patel AP, Wang M, Fahed AC, Mason-Suares H, Brockman D, Pelletier R, Amr S, Machini K, Hawley M, Witkowski L, Koch C, Philippakis A, Cassa CA, Ellinor PT, Kathiresan S, Ng K, Lebo M, Khera AV.JAMA Netw Open. 2020 Apr 1;3(4):e203959. doi: 10.1001/jamanetworkopen.2020.3959.PMID: 32347951 Free PMC article.
• High-frequency actionable pathogenic exome variants in an average-risk cohort.

  Rego S, Dagan-Rosenfeld O, Zhou W, Sailani MR, Limcaoco P, Colbert E, Avina M, Wheeler J, Craig C, Salins D, Röst HL, Dunn J, McLaughlin T, Steinmetz LM, Bernstein JA, Snyder MP.Cold Spring Harb Mol Case Stud. 2018 Dec 17;4(6):a003178. doi: 10.1101/mcs.a003178. Print 2018 Dec.PMID: 30487145 Free PMC article.
• Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.

  Batalini F, Peacock EG, Stobie L, Robertson A, Garber J, Weitzel JN, Tung NM.Breast Cancer Res. 2019 Sep 18;21(1):107. doi: 10.1186/s13058-019-1193-1.PMID: 31533767 Free PMC article. Review.